Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.68 |
| ▸ | FAP | Q12884 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Anhydrous SCHEMBL3967109 | 1.00 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL400718 | 1.00 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL20295138 | 1.00 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL19586794 | 1.00 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL39724 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL497725 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL29355255 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL2040329 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL18894359 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL18492311 | 0.98 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107011382-A | A kind of tenofovir prodrug and preparation method thereof | 单爱莲 | 2017-08-04 | — | — | CN | claimed |
| WO-2025151774-A1 | TREATING INFLAMMATORY RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-11826375-B2 | Phosphinic amide prodrugs of tenofovir | MERCK SHARP & DOHME LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220143050-A1 | mTOR Inhibitor | MURATA, Kazumoto (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3559011-B1 | ANTIVIRAL ESTER PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3954389-A1 | MTOR INHIBITOR | Murata, Kazumoto (JP) | 2022-02-16 | — | — | EP | disclosed |
| CN-113683641-A | Tenofovir phosphate crystal form d and preparation and application thereof | 西安新通药物研究股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-113683641-A | Tenofovir phosphate crystal form d and preparation and application thereof | 西安新通药物研究股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-113683641-A | Tenofovir phosphate crystal form d and preparation and application thereof | 西安新通药物研究股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-113583049-A | Tenofovir phosphate e crystal form and preparation and application thereof | 西安新通药物研究股份有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-104903334-B | Tenofovir prodrug and application thereof in medicine | 江苏豪森药业集团有限公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-106188139-A | Tenofovir list benzyl ester phosphoamide prodrug, its preparation method and application | 江苏天士力帝益药业有限公司 | 2016-12-07 | — | — | CN | disclosed |
| CN-104903334-A | Tenofovir prodrug and application thereof in medicine | JIANGSU HANSOH PHARMACEUTICAL | 2015-09-09 | — | — | CN | disclosed |
| US-20150225433-A1 | TENOFOVIR PRODRUG AND PHARMACEUTICAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-08-13 | — | — | US | disclosed |
| EP-2891658-A1 | TENOFOVIR PRODRUG AND PHARMACEUTICAL USES THEREOF | Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) | 2015-07-08 | — | — | EP | disclosed |
| WO-2013132314-A1 | TENOFOVIR PHOSPHATE, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013132314-A1 | TENOFOVIR PHOSPHATE, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2013-09-12 | — | — | WO | disclosed |
| WO-2012041015-A1 | METHOD FOR PREPARING ACYCLIC NUCLEOSIDE MONOPHOSPHATE COMPOUND AS ANTIVIRAL DRUG | 中国医学科学院医药生物技术研究所 (CN) | 2012-04-05 | — | — | WO | disclosed |
| CN-1319520-C | Liposome and lipid composite preparation of nucleoside phosphoric acid compound | SHANGHAI COMM UNIVERSITY (CN) | 2007-06-06 | — | — | CN | disclosed |
| CN-1679514-A | Liposome and lipid composite preparation of nucleoside phosphoric acid compound | UNIV SHANGHAI COMMUNICATION (CN) | 2005-10-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143050-A1 | mTOR Inhibitor | MTOR, RICTOR, RPTOR | CYP3A4 602/4885CYP2D6 739/4885FAP 1685/4885 |
| US-20150225433-A1 | TENOFOVIR PRODRUG AND PHARMACEUTICAL USES THEREOF | SLC10A1, HPRT1, SLC5A1 | CYP3A4 35/4885CYP2D6 14/4885FAP 414/4885 |
| US-11826375-B2 | Phosphinic amide prodrugs of tenofovir | TYMP, PPA1, PNP | CYP3A4 1743/4885CYP2D6 2129/4885FAP 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.